7-chloro-4-quinolinyl hydrazones: A promising and potent class of antileishmanial compounds

Chemical Biology and Drug Design

Volumn 81, Issue 5, 2013, Pages 658-665

  Coimbra, Elaine S ^a   Antinarelli, Luciana M R ^a   da Silva, Adilson D ^a   Bispo, Marcelle L F ^b,c   Kaiser, Carlos R ^c   De Souza, Marcus V N ^b,c  

^a FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

7 chloro 4 quinolinyl hydrazones; Amodiaquine; Antileishmanial

Indexed keywords

ANTILEISHMANIAL AGENT; HYDRAZONE DERIVATIVE;

AMASTIGOTE; ANIMAL CELL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SELECTIVITY; DRUG SPECIFICITY; IC 50; IN VITRO STUDY; LEISHMANIA BRAZILIENSIS; LEISHMANIA CHAGASI; LEISHMANIA MAJOR; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIPROTOZOAL AGENTS; HUMANS; HYDRAZONES; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS, CUTANEOUS; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C;

LEISHMANIA BRAZILIENSIS; MURINAE;

EID: 84876871202     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12112     Document Type: Article

References (21)

1. Croft S.L., Coombs G.H. (2003) Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol;19:502-508.
2. Mishra J., Saxena A., Singh S. (2007) Chemotherapy of leishmaniasis: past, present and future. Curr Med Chem;14:1153-1169.
3. Santos D.O., Coutinho C.E.R., Madeira M.F., Bottino C.G., Vieira R.T., Nascimento A.B., Bourguignon S.C., Corte-Real S., Pinho R.S., Rodrigues C.R., Castro H.C. (2008) Leishmaniasis treatment - a challenge that remains: a review. Parasitol Res;103:1-10.
4. Singh S., Sivakumar R. (2004) Challenges and new discoveries in the treatment of leishmaniasis. J Infect Chemother;10:307-315.
5. Desjeux P. (2004) Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis;27:305-318.
6. Coimbra E.S., Carvalhaes R., Grazul R.M., Machado P.A., De Souza M.V.N., Da Silva A.D. (2010) Synthesis, cytotoxicity and antileishmanial activity of some N-(2-(indol-3-yl)ethyl)-7-chloroquinolin-4-amines. Chem Biol Drug Des;75:628-631.
7. Guglielmo S., Bertinaria M., Rolando B., Crosetti M., Fruttero R., Yardley V., Croft S.L., Gasco A. (2009) A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity. Eur J Med Chem;44:5071-5079.
8. De Mello H., Echevarria A., Bernardino A.M., Canto-Cavalheiro M., Leon L.L. (2004) Antileishmanial pyrazolopyridine derivatives: synthesis and structure-activity relationship analysis. J Med Chem;47:5427-5432.
9. Coimbra E.S., Da Silva A.D., Dias R.M.P., Corrales R.C.N., Bispo M.L.F., Kaiser C.R., De Souza M.V.N. (2011) Amodiaquine analogs. Synthesis and anti-leishmanial activity. Med J Chem;3:106-113.
10. Candea A.L.P., Ferreira M.L., Pais K.C., Cardoso L.N.F., Kaiser C.R., Henriques M.G.M.O., Lourenço M.C.S., Bezerra F.A.F.M., De Souza M.V.N. (2009) Synthesis and antitubercular activity of 7-chloro-4-quinolinyl hydrazones derivatives. Bioorg Med Chem Lett;19:6272-6274.
11. Ferreira M.L., Gonçalves R.S.B., Cardoso L.N.F., Kaiser C.R., Candea A.L.P., Henriques G.M.O.M., Lourenço M.C.S., Bezerra F.A.F.M., De Souza M.V.N. (2010) Synthesis and antitubercular activity of heteroaromatic isonicotinoyl and 7-chloro-4-quinolinyl hydrazone derivatives. Sci World J;10:1347-1355.
12. Mossman T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods;65:55-58.
13. Carmo A.M., Silva F.M., Machado P.A., Fontes A.P., Pavan F.R., Leite C.Q., Leite S.R., Coimbra E.S., Da Silva A.D. (2011) Synthesis of 4-aminoquinoline analogues and their platinum(II) complexes as new antileishmanial and antitubercular agents. Biomed Pharmacother;65:204-209.
14. Green L.C., Wagner D.A., Glogwski J., Skipper P.L., Wishnok J.S., Tannenbaum S.R. (1982) Analysis of nitrate, nitrite, and nitrate in biological fluids. Anal Biochem;126:131-138.
15. 3 (edelfosine) and amphotericin B. Acta Trop;81:151-157.
16. Vermeersch M., Da Luz R.I., Toté K., Timmermans J.P., Cos P., Maes L. (2009) In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob Agents Chemother;53:3855-3859.
17. Tempone A.G., Martins de Oliveira C., Berlinck R.G. (2011) Current approaches to discover marine antileishmanial natural products. Planta Med;77:572-575.
18. Singh N., Kumar M., Singh R.K. (2012) Leishmaniasis: current status of available drugs and new potential drug targets. Asian Pac J Trop Med;5:485-497.
19. De Muylder G., Ang K.K., Chen S., Arkin M.R., Engel J.C., McKerrow J.H. (2011) A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit. PLoS Negl Trop Dis;5:e1253.
20. Evans T.G., Thai L., Granger D.L., Hibbs J.B. Jr (1993) Effect of in vivo inhibition of nitric oxide production in murine leishmaniasis. J Immunol;151:907-915.
21. Frézard F., Demicheli C., Ribeiro R.R. (2009) Pentavalent antimonials: new perspectives for old drugs. Molecules;14:2317-2336.